Buprenorphine itself does not rot teeth the way sugar does, but the sublingual and buccal formulations used to treat opioid use disorder create a perfect storm of acid exposure, reduced saliva buffering, and bacterial growth right where the drug dissolves. A large study published in JAMA found that the rate of dental caries or tooth loss was roughly twice as high among people taking sublingual buprenorphine-naloxone compared with those using transdermal buprenorphine patches or oral naltrexone, two medications that bypass the mouth entirely. The problem became prominent enough that the FDA issued a formal safety warning in 2022, and the science explaining why has been filling in rapidly since then.
What the FDA Warning Was About
In 2022, the U.S. Food and Drug Administration flagged oral health problems connected to transmucosal buprenorphine formulations, meaning films and tablets that dissolve under the tongue or against the cheek.1PubMed Central. Oral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al. The warning was based on reports of severe dental problems, including tooth decay, cavities, oral infections, and tooth loss, even in patients who had no prior history of dental issues. This was not a recall or a recommendation to stop treatment. The FDA’s message was that clinicians and patients should be aware of the risk and take preventive steps. Still, the announcement shook a treatment community that had long viewed buprenorphine as one of the safest medications available for opioid use disorder.
The Acid Problem in the Formulation
The most direct cause of enamel damage is the acidity of the drug formulation itself. Sublingual buprenorphine tablets and films contain acid excipients, ingredients added to keep the drug in a form that can dissolve and absorb through the lining of the mouth. These acids lower the local pH in the oral cavity and reduce saliva’s ability to neutralize the acid.2International Journal of Pharmaceutics. Dental caries associated with medications for opioid use disorder: drug effects, formulation factors, or both? That matters because tooth enamel begins to dissolve when the pH at the tooth surface drops below roughly 5.5.3Science and Innovation. MECHANISM OF DENTAL ENAMEL DEMINERALIZATION: THE ROLE OF ORGANIC ACIDS, PH, AND HYDROXYAPATITE DISSOLUTION
Enamel erosion from acid is not an on-off switch. The speed at which mineral dissolves depends on how acidic the solution is, how long it sits on the tooth, and which specific acids are involved. Enamel dissolves faster at lower pH, and this sensitivity is more pronounced for enamel than for the dentin underneath it.4PubMed. Effects of pH and acid concentration on erosive dissolution of enamel, dentine, and compressed hydroxyapatite What makes buprenorphine formulations especially damaging is that the exposure happens repeatedly, once or twice daily, and the tablet or film is held against the teeth and gums for several minutes while it dissolves. Repeated low-pH exposure over months and years creates characteristic erosion patterns where the mineral structure of the enamel breaks down progressively.5PubMed. Pathogenesis and modifying factors of dental erosion
The exact pH of a given buprenorphine product varies by manufacturer and formulation type, but the principle is consistent: every time the film or tablet dissolves, the area immediately around it becomes an acid bath for your enamel. Unlike drinking an acidic beverage, which washes past the teeth relatively quickly, a sublingual tablet sits in one spot. The acid concentrates where the tablet meets the teeth, often affecting the lower front teeth and adjacent surfaces most severely.
Buprenorphine Accumulates in Saliva Glands
Acidity alone does not explain the full picture. Research has uncovered a second mechanism that is uniquely tied to buprenorphine’s pharmacology rather than just its formulation. After administration, buprenorphine and its active metabolite norbuprenorphine accumulate in the salivary glands at concentrations significantly higher than what appears in the blood. This happens regardless of whether the drug is given sublingually or intravenously, meaning it is a property of the drug itself, not just the route of delivery. The concentration of buprenorphine in oral fluid tracks closely with the concentration in salivary gland tissue rather than blood levels, suggesting the glands act as a reservoir that keeps dripping the drug back into the mouth long after the tablet has dissolved.6PubMed Central. Buprenorphine Salivary Gland Accumulation Sustaining High Oral Fluid Exposure and Increasing the Risk of Streptococcus mutans Biofilm Formation
Why does this matter for teeth? Because high concentrations of buprenorphine and its metabolites promote the formation of biofilms by Streptococcus mutans, the bacterium most closely linked to dental cavities.6PubMed Central. Buprenorphine Salivary Gland Accumulation Sustaining High Oral Fluid Exposure and Increasing the Risk of Streptococcus mutans Biofilm Formation A biofilm is the sticky layer of bacteria that clings to tooth surfaces and produces its own acid as it feeds on sugars. Thicker, more robust biofilms mean more acid production right at the enamel surface and greater difficulty for saliva to wash it away. So even between doses, the drug lingering in salivary secretions is quietly encouraging the growth of cavity-causing bacteria.
Dry Mouth Compounds the Damage
Opioids as a class tend to reduce saliva production. Buprenorphine is a partial opioid agonist, and while its effects on salivary flow are generally milder than those of full agonists like methadone, many patients still experience dry mouth. Saliva is the mouth’s primary defense against both acid and bacterial growth. It contains calcium and phosphate ions that help remineralize enamel after acid attacks, and it physically flushes food particles and bacteria off teeth. When saliva production drops, the mouth loses its main self-cleaning and repair system, leaving teeth far more vulnerable to both erosion and cavities.7PubMed Central. The Oral Microbial Ecosystem in Age-Related Xerostomia: A Critical Review
This creates an unfortunate feedback loop. The acidic formulation reduces the buffering capacity of whatever saliva is present. The drug itself may reduce how much saliva flows. And the drug accumulating in salivary gland tissue encourages the very bacteria that thrive in acidic, low-saliva environments. Each mechanism worsens the conditions the others exploit.
How the Risk Compares to Other Formulations and Medications
The evidence is fairly clear that the oral route of administration is the problem, not buprenorphine as a molecule in general. In the JAMA study, people taking sublingual buprenorphine-naloxone had about 8.2 dental events per 1,000 person-years, compared with 3.5 for transdermal buprenorphine and 3.8 for oral naltrexone. The hazard ratio was roughly 1.6 to 1.7, meaning the sublingual group had about 60 to 70 percent higher risk of caries or tooth loss.8JAMA. Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease Transdermal patches deliver buprenorphine through the skin and skip the mouth entirely, which is why that group’s dental outcomes were comparable to naltrexone (a completely different medication taken as a pill that is swallowed, not dissolved in the mouth).
Pharmacovigilance analyses of the FDA’s adverse event reporting system paint an even starker picture. Sublingual buprenorphine products were associated with a reporting rate of dental disorders about 20 times higher than the background rate across all other drugs.9PubMed. Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of Administration Buccal (cheek-dissolved) formulations also showed elevated reporting, though at a lower rate. Non-transmucosal routes like patches and implants did not show the same signal, reinforcing that mouth contact is the driving factor. A separate pharmacovigilance study found that sublingual and buccal buprenorphine was associated with about six times the dental problem reporting rate compared with methadone, itself a drug long known to carry dental risks.10PubMed. Sublingual/Buccal buprenorphine and dental problems: a pharmacovigilance study
These reporting-based numbers are not direct measures of how many people develop cavities. Adverse event databases reflect what gets reported, and heightened awareness after the 2022 FDA warning likely increased reporting. But the consistency across multiple studies and analysis methods makes it hard to dismiss the signal as an artifact.
Confounding Factors That Muddy the Picture
It would be dishonest to pin all the dental problems seen in buprenorphine patients on the drug alone. People being treated for opioid use disorder typically arrive with significant oral health disadvantages that preceded their treatment. Years of active substance use often mean poor nutrition, high sugar intake, irregular dental care, and sometimes direct damage from smoking or drug use itself. Studies comparing opioid-dependent patients to matched controls consistently find worse dental outcomes in the opioid group, with lower education and lower socioeconomic status contributing independently to higher rates of decayed, missing, and filled teeth.11PubMed Central. Oral health status and its determinants among opiate dependents: a cross-sectional study
Researchers studying buprenorphine’s dental effects have acknowledged this difficulty openly. In one cohort study, the control group consisted of people already receiving regular, high-quality dental care, which could exaggerate the gap between groups.12Frontiers in Oral Health. Impact of opioid abuse on oral health: a retrospective cohort study Even the JAMA study, which compared sublingual buprenorphine to other medications rather than to untreated populations, cannot fully control for differences in diet, dental hygiene habits, smoking rates, or prior substance use between groups. The elevated risk is real, but the exact size of the contribution from the formulation versus the population’s baseline risk remains genuinely uncertain.
What You Can Do to Protect Your Teeth
If you take sublingual or buccal buprenorphine, there are practical steps that can reduce the damage. Clinical guidance published in dental and addiction medicine journals converges on a few core recommendations:13The Journal of the American Dental Association. Orally dissolving buprenorphine for opioid use disorder linked to caries
- Rinse with water: Once the tablet or film has fully dissolved, take a sip of water, swish it around your mouth, and swallow. This helps wash away residual acid and drug from tooth surfaces.
- Wait to brush: Do not brush your teeth immediately after taking the medication. Enamel softened by acid is more vulnerable to abrasion from a toothbrush. Waiting at least an hour allows saliva to begin remineralizing the surface before you scrub it.
- Use fluoride: A prescription-strength fluoride toothpaste or rinse can help strengthen enamel against acid attacks. Your dentist can prescribe a high-fluoride product if over-the-counter options are not enough.
- Stay hydrated: Drinking water throughout the day helps counteract dry mouth. Sugar-free gum or lozenges containing xylitol can also stimulate saliva flow.
- Keep dental appointments: Regular professional cleanings and exams catch problems early. If your dentist knows you take buprenorphine, they can monitor vulnerable areas more closely.
A baseline dental evaluation before or shortly after starting buprenorphine treatment is also recommended, along with ongoing attention to any changes in your teeth or gums.14PubMed Central. Sublingual buprenorphine and dental problems: a case series These precautions are not difficult, but they require awareness, and for years neither patients nor many prescribers were told about the risk at all.
Why Dental Care Is Hard to Access for This Population
Knowing what to do and being able to do it are different things. A qualitative study of patients on opioid maintenance treatment found multiple non-financial barriers to dental care, including difficulty attending scheduled appointments, anxiety and fear of dental procedures, frustration when the care offered did not match their expectations, and perceived stigma from dental staff.15PubMed Central. Non-financial barriers in oral health care: a qualitative study of patients receiving opioid maintenance treatment and professionals’ experiences Some patients reported feeling judged or treated dismissively when they disclosed their medication history.
Financial barriers compound these issues. In many parts of the United States, Medicaid dental coverage for adults is limited or nonexistent, and private dental insurance often has caps that are quickly exceeded when extensive restorative work is needed. The people most likely to be on buprenorphine treatment are often in the income brackets least likely to have robust dental coverage. This creates a situation where the group most at risk for drug-related dental damage is also the group with the fewest resources to address it. Prescribers who recommend regular dental visits should recognize that the recommendation alone may not be enough and that helping patients navigate coverage and referral pathways is part of responsible care.
Should You Worry Enough to Switch Medications?
The dental risk associated with sublingual buprenorphine is real and well-documented, but it has to be weighed against the life-saving benefit of the medication itself. Buprenorphine dramatically reduces the risk of fatal overdose, helps people stabilize their lives, and is one of the most effective treatments available for opioid use disorder. Stopping or avoiding buprenorphine because of dental concerns would be a dangerous trade-off for most patients.
That said, alternatives do exist for some people. Extended-release buprenorphine injections, which are given monthly and bypass the mouth entirely, eliminate the formulation-related acid exposure. Whether they also eliminate the salivary gland accumulation effect has not been studied as thoroughly, but removing the repeated sublingual acid bath would address the single largest mechanism. Transdermal buprenorphine patches, which showed dental event rates comparable to non-buprenorphine medications in the JAMA study, are another option, though they are primarily approved for pain management rather than opioid use disorder in most settings.8JAMA. Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease The choice depends on clinical appropriateness, insurance coverage, and patient preference, and it should always be made in conversation with a prescriber rather than unilaterally.
Could Better Formulations Fix This?
One of the more promising directions in the research is the suggestion that the formulation, not the drug, is the primary culprit for the acid-mediated damage. If the acidic excipients in current sublingual products could be replaced or buffered without compromising drug absorption, a significant portion of the dental risk could theoretically be eliminated. Researchers have explicitly pointed to formulation factors like acid excipients and their effects on local pH as modifiable targets.2International Journal of Pharmaceutics. Dental caries associated with medications for opioid use disorder: drug effects, formulation factors, or both?
This matters because sublingual buprenorphine remains the most widely prescribed form of the drug, and many patients prefer it over injections. A reformulated sublingual product with a higher pH could retain the convenience of the current delivery method while drastically reducing enamel erosion. Whether pharmaceutical companies will pursue this proactively or whether it will require regulatory pressure is an open question, but the scientific rationale for a better formulation is straightforward. The salivary gland accumulation and biofilm effects would remain, since those are properties of the drug molecule itself, but removing the repeated acid exposure would eliminate what appears to be the dominant driver of the problem.
For now, patients and clinicians are working with the tools available: water rinses, delayed brushing, fluoride supplementation, and regular dental monitoring. These are simple interventions, and while they cannot eliminate the risk entirely, they can meaningfully reduce it. The broader challenge is making sure people actually know about the risk in the first place, something the 2022 FDA warning helped but did not fully solve, especially for patients who had already been on the medication for years before the announcement.